Cyxone has decided to apply for a listing of its share on Nasdaq Stockholm Main Market

Cyxone (publ.) announced today that its Board of Directors has decided to apply for a listing of the company’s share on Nasdaq Stockholm Main Market. The company will prepare to submit an application in the first quarter of 2022. Cyxone is currently listed on Nasdaq First North Growth Market.

Cyxone develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Its most advanced project, Rabeximod, is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. Further, the company is developing T20K – a Phase 1 candidate drug for treatment of multiple sclerosis. Cyxone’s share is listed on Nasdaq First North Growth Market since June 2016. A listing on Nasdaq Stockholm Main Market is expected to generate increased visibility for the company on a national and international level.

"We are excited to initiate preparations for an up-listing of Cyxone’s share to Nasdaq Stockholm Main Market. This initiative is a natural next step in the company’s development, adding to our opportunities in building an even wider and stronger shareholder base," comments Cyxone’s CEO, Tara Heitner.

Cyxone has appointed KMPG to support the company during the up-listing process.

Tara Heitner, CEO
Tel: +46 70 781 88 08
Email: tara.heitner@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com